Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect

The availability of new potent systemic therapies for urothelial carcinoma may change the way we use standard chemotherapy perioperatively. In particular, identifying which patients with muscle-invasive bladder cancer (MIBC) would benefit from adjuvant chemotherapy (AC) is compelling. From a multice...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eur Urol
Hauptverfasser: Pederzoli, Filippo, Bandini, Marco, Briganti, Alberto, Plimack, Elizabeth R., Niegisch, Günter, Yu, Evan Y., Bamias, Aristotelis, Agarwal, Neeraj, Sridhar, Srikala S., Sternberg, Cora N., Vaishampayan, Ulka N., Théodore, Christine, Rosenberg, Jonathan E., Harshman, Lauren C., Bellmunt, Joaquim, Galsky, Matthew D., Gallina, Andrea, Salonia, Andrea, Montorsi, Francesco, Necchi, Andrea
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852645/
https://ncbi.nlm.nih.gov/pubmed/31303258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.06.032
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge